Synairgen Plc (SNG) – Strategy, SWOT and Corporate Finance Report

Synairgen Plc (SNG) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma, COVID-19 and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) in Phase II clinical trials for chronic obstructive pulmonary disease (COPD) and COVID-19. The company in partnership with Pharmaxis investigating, lysyl oxidase-like protein 2 (LOXL2), a small molecule inhibitor in Phase I clinical trials for the treatment of fibrotic disease. Synairgen develops drugs and tissue models based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells, and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Scope

• Detailed information on Synairgen Plc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Synairgen Plc in the form of a SWOT analysis

• An in-depth view of the business model of Synairgen Plc including a breakdown and examination of key business segments

• News about Synairgen Plc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Synairgen Plc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Synairgen Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Oxagen Ltd

Verona Pharma Plc

Halo Therapeutics Ltd

Theravance Biopharma Inc

Napp Pharmaceuticals Ltd

ALK-Abello AS

Novartis AG

GSK plc

Table of Contents